Stachowicz-Stencel T, Bien E, Balcerska A, Godzinski J, Synakiewicz A, Perek-Polnik M, Kurylak A, Pietras W, Kuzmicz M, Mizia-Malarz A, Rybczynska A, Nurzynska-Flak J
Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University of Gdansk, Poland.
Klin Padiatr. 2011 May;223(3):138-41. doi: 10.1055/s-0031-1275349. Epub 2011 Apr 20.
Renal cell carcinoma (RCC) in children is rare, accounting for approximately 1.9-6% of all pediatric renal malignancies. The aim of this study was to transmit our experience in the treatment of RCC in Polish children.
Clinical data from 21 children (6.3-18 years old) with RCC treated between 1992 and 2009 at Polish pediatric oncological centers were analyzed.
In 2 patients, RCC developed as a second malignancy after neuroblastoma or astrocytoma fibrillare, respectively. In 6 patients, initial diagnoses based on imaging studies were unilateral Wilms' tumor, leading to preoperative chemotherapy. The remaining patients underwent surgery at the beginning of treatment. According to the AJCC/TNM staging system, 14 patients had stage I, 5-II, 1-III, and 1-IV. Nephrectomy was performed in 19 patients, heminephrectomy in one, and biopsy in another. Histopathological diagnoses were clear-cell RCC (18 patients), papillary RCC (2 patients), and chromophobe RCC (1 patient). 10 patients were treated with chemotherapy, with or without IL-2, INFα, and antiangiogenic agents. 2 patients died due to disease progression.
RCC in children is mostly operable at diagnosis, resulting in good prognosis. The role of adjuvant chemo- and immunotherapies is unclear. Neoadjuvant chemotherapy proven for children with Wilms' tumors is ineffective, but the delay in adequate therapy did not worsen the outcome if complete nephrectomy is done subsequently.
儿童肾细胞癌(RCC)较为罕见,约占所有小儿肾恶性肿瘤的1.9 - 6%。本研究旨在分享我们在波兰儿童RCC治疗方面的经验。
分析了1992年至2009年期间在波兰儿科肿瘤中心接受治疗的21例(6.3 - 18岁)RCC患儿的临床资料。
2例患儿分别在患神经母细胞瘤或纤维型星形细胞瘤后发生RCC,为第二原发恶性肿瘤。6例患儿最初根据影像学检查诊断为单侧肾母细胞瘤,接受了术前化疗。其余患儿在治疗开始时接受了手术。根据美国癌症联合委员会(AJCC)/国际抗癌联盟(TNM)分期系统,14例为Ⅰ期,5例为Ⅱ期,1例为Ⅲ期,1例为Ⅳ期。19例行肾切除术,1例行半肾切除术,1例行活检。组织病理学诊断为透明细胞RCC(18例)、乳头状RCC(2例)和嫌色细胞RCC(1例)。10例患儿接受了化疗,联合或不联合白细胞介素-2(IL - 2)、α干扰素(INFα)和抗血管生成药物。2例患儿因疾病进展死亡。
儿童RCC在诊断时大多可手术切除,预后良好。辅助化疗和免疫治疗的作用尚不清楚。已证实对肾母细胞瘤患儿有效的新辅助化疗对RCC无效,但如果随后进行完整的肾切除术,适当治疗的延迟并未使预后恶化。